A New Combination of Factor XA Inhibition and Standard Antiplatelet Therapy to Prevent More Recurrent Cardiovascular Events in Acute Coronary Syndrome (ACS)

Speakers:

Christoph Bode,¹ Gabriel Steg,² Gilles Montalescot,³ Robert Welsh⁴

1. Department of Cardiology and Angiology I, Heart Center Freiburg University, Freiburg, Germany; Department of Medical Intensive Care, University Clinic Freiburg, Freiburg, Germany
2. Hôpital Bichat, Assistance Publique – Hôpitaux de Paris Université Paris – Diderot, Sorbonne Paris Cité, INSERM U-698 French Alliance for Cardiovascular Trials, Paris, France
3. Hôpital de la Pitié-Salpêtrière, Paris, France
4. Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada

Disclosure:

The speakers were contracted by EuroPCR to participate in this satellite symposium.

Acknowledgements:

Writing assistance provided by Trilogy Writing and Consulting Ltd.

Support:

The publication of this article was funded by Bayer HealthCare Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily of Bayer.

Citation:

EMJ Int Cardiol. 2013;1[1]:20-33. DOI/10.33590/emjintcardiol/10312927. https://doi.org/10.33590/emjintcardiol/10312927.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.